Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Therapeutic potential of endothelin receptor antagonists and nitric oxide donors in pulmonary hypertension
Autore:
Tilton, RG; Brock, TA; Dixon, RAF;
Indirizzi:
Texcas Biotechnol Corp, Dept Pharmacol, Houston, TX 77030 USA Texcas Biotechnol Corp Houston TX USA 77030 rmacol, Houston, TX 77030 USA
Titolo Testata:
EXPERT OPINION ON INVESTIGATIONAL DRUGS
fascicolo: 7, volume: 10, anno: 2001,
pagine: 1291 - 1308
SICI:
1354-3784(200107)10:7<1291:TPOERA>2.0.ZU;2-V
Fonte:
ISI
Lingua:
ENG
Soggetto:
VASCULAR SMOOTH-MUSCLE; CONVERTING ENZYME ECE-1; ORGANIC NITRATES; GENE-EXPRESSION; MESSENGER-RNA; PREPROENDOTHELIN-1 GENE; VASOCONSTRICTOR PEPTIDE; FUNCTIONAL EXPRESSION; MOLECULAR MECHANISMS; TARGETED DISRUPTION;
Keywords:
endothelin; endothelin receptors; ETA and ETB antagonists; nitric oxide; NO donors; pulmonary hypertension;
Tipo documento:
Review
Natura:
Periodico
Settore Disciplinare:
Life Sciences
Citazioni:
166
Recensione:
Indirizzi per estratti:
Indirizzo: Tilton, RG Texcas Biotechnol Corp, Dept Pharmacol, Houston, TX 77030 USA Texcas Biotechnol Corp Houston TX USA 77030 ston, TX 77030 USA
Citazione:
R.G. Tilton et al., "Therapeutic potential of endothelin receptor antagonists and nitric oxide donors in pulmonary hypertension", EXPERT OP I, 10(7), 2001, pp. 1291-1308

Abstract

Pulmonary hypertension can occur idiopathically as a primary disorder of the pulmonary circulation or more commonly, it can exist as a haemodynamic manifestation of a wide variety of pulmonary and cardiovascular diseases, including acute lung injury, chronic obstructive lung disease, congenital heart disease, mitral stenosis, chronic left-sided congestive heart failure and connective tissue diseases such as scleroderma. Pulmonary hypertension isassociated with changes in vascular tone as well as vascular structure, with the relative contribution of each dependent upon the aetiology of the increased pulmonary vascular resistance. Most currently available treatments utilise anticoagulants as well as vasodilator drugs that only attenuate thevasoconstrictive component of the disease. The latter category includes oral calcium channel blockers, iv. and aerosolised prostacyclin analogues andinhaled nitric oxide but all three classes of vasodilators have disadvantages and limitations. Treatment with vasodilators is often ineffective in patients with longstanding pulmonary hypertension in which structural changescontribute significantly to the pulmonary hypertension, blood flow obstruction and right heart failure. In view of the immense clinical need, new therapies are being developed by pharmaceutical companies to treat pulmonary hypertension. This update will focus on the current development status of endothelin receptor antagonists and nitric oxide donors for the treatment of pulmonary hypertension.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 04/06/20 alle ore 01:45:26